Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies

Tyler E Smith,Maya Madhavan,Daniel Gratch,Aneek Patel,Valerie Saha,Carrie Sammarco,Zoe Rimler,Guadalupe Zuniga,Dunia Gragui,Leigh Charvet,Gary Cutter,Lauren Krupp,Ilya Kister,Lana Zhovtis Ryerson

Multiple Sclerosis and Related Disorders（2022）

引用 18|浏览5

暂无评分

摘要

•Rituximab was a predictor of severe COVID-19•No disease modifying therapies showed increased risk for COVID-19•Those on anti-CD20 therapy should take precautions during the COVID-19 pandemic

查看译文

关键词

Multiple Sclerosis,COVID-19,disease severity,disease-modifying therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要